source
- FDA Completes Type A Meeting Following CRL for Tabelecleucel in EBV+ R/R Post-Transplant Lymphoproliferative DiseaseThe FDA and Atara Biotherapeutics completed a Type A meeting to discuss the CRL for tabelecleucel in post-transplant lymphoproliferative disease.onclive · 4mo ago↗ source
- ASCO 2026 TNBC Deep Dive: Breast Cancer Experts Preview Practice-Informing StudiesExperts spotlight the triple-negative breast cancer abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.onclive · 4mo ago↗ source
- Angelini to buy Catalyst in $4B play for rare neuro drugsThe acquisition hands the Italian pharma a group of medicines approved to treat various CNS disorders and gives it wider market access in the U.S.